In 2008 , Boehringer Ingelheim posted net sales of $ 17 billion ( 11.6 billion euro ) while spending one-fifth of net sales in its largest business segment , Prescription Medicines , on research and development. sensitivity of tumors to gefitinib and erlotinib . "